prominent to improve the anticancer effect. Based on I-1, a series of agents targeting COX-2 and Topo I were designed by combining fenamates and phenols. The optimal compound 1H-30 displayed an enhanced inhibitory effect on COX-2 compared to tolfenamic acid and I-1 and showed better inhibition of Topo I than I-1. Importantly, 1H-30 showed potential anticancer effects and suppressed the activation of the
鉴于炎症与癌症之间的密切联系,结合抗炎治疗对于提高抗癌效果是突出的。在I-1的基础上,结合fenamates和
酚类设计了一系列靶向COX-2和Topo I的药物。与
托芬那酸和I-1相比,最佳化合物1H-30对COX-2的抑制作用增强,对Topo I的抑制作用优于I-1。重要的是,1H-30显示出潜在的抗癌作用并抑制癌细胞中 NF-κB 通路的激活。1H-30抑制 NF-κB 的核转位并抑制 RAW264.7 中 NO、COX-2 和 IL-1β 的产生。体内,1H-30显示可接受的药代动力学参数,在不影响体重的情况下降低肿瘤生长,下调 COX-2 和 MMP-9,并在 CT26.WT 荷瘤小鼠中诱导细胞凋亡。因此,1H-30作为一种潜在的 Topo I/COX-2
抑制剂,具有抗炎和抗癌作用,可抑制 NF-κB 通路,有望用于胃肠道癌症治疗。